hVIVO plc
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker an… Read more
Market Cap & Net Worth: hVIVO plc (HVO)
hVIVO plc (LSE:HVO) has a market capitalization of $660.55K (GBX5.43 Billion) as of March 19, 2026. Listed on the LSE stock exchange, this UK-based company holds position #45974 globally and #930 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying hVIVO plc's stock price GBX7.90 by its total outstanding shares 687216180 (687.22 Million).
hVIVO plc Market Cap History: 2015 to 2026
hVIVO plc's market capitalization history from 2015 to 2026. Data shows change from $1.74 Million to $660.55K (-9.63% CAGR).
Index Memberships
hVIVO plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$41.09 Million | 0.01% | #158 of 722 |
Weight: hVIVO plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
hVIVO plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how hVIVO plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.03x
hVIVO plc's market cap is 0.03 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.16x
hVIVO plc's market cap is 0.16 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.74 Million | $8.47 Million | $11.07K | 0.21x | 156.84x |
| 2016 | $1.84 Million | $15.27 Million | $453.48K | 0.12x | 4.05x |
| 2017 | $928.56K | $15.45 Million | -$1.37 Million | 0.06x | N/A |
| 2018 | $137.27K | $12.55 Million | -$4.30 Million | 0.01x | N/A |
| 2019 | $367.38K | $3.28 Million | -$5.59 Million | 0.11x | N/A |
| 2020 | $2.08 Million | $20.60 Million | -$10.79 Million | 0.10x | N/A |
| 2021 | $1.86 Million | $36.86 Million | -$74.00K | 0.05x | N/A |
| 2022 | $807.45K | $48.48 Million | -$776.00K | 0.02x | N/A |
| 2023 | $1.97 Million | $56.04 Million | $16.11 Million | 0.04x | 0.12x |
| 2024 | $1.71 Million | $62.73 Million | $10.65 Million | 0.03x | 0.16x |
Competitor Companies of HVO by Market Capitalization
Companies near hVIVO plc in the global market cap rankings as of March 19, 2026.
Key companies related to hVIVO plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
hVIVO plc Historical Marketcap From 2015 to 2026
Between 2015 and today, hVIVO plc's market cap moved from $1.74 Million to $ 660.55K, with a yearly change of -9.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX660.55K | +25.40% |
| 2025 | GBX526.77K | -69.27% |
| 2024 | GBX1.71 Million | -13.05% |
| 2023 | GBX1.97 Million | +144.16% |
| 2022 | GBX807.45K | -56.52% |
| 2021 | GBX1.86 Million | -10.85% |
| 2020 | GBX2.08 Million | +467.04% |
| 2019 | GBX367.38K | +167.64% |
| 2018 | GBX137.27K | -85.22% |
| 2017 | GBX928.56K | -49.45% |
| 2016 | GBX1.84 Million | +5.81% |
| 2015 | GBX1.74 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of hVIVO plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $660.55K USD |
| MoneyControl | $660.55K USD |
| MarketWatch | $660.55K USD |
| marketcap.company | $660.55K USD |
| Reuters | $660.55K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.